시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 뮤코다당증 치료 시장 보고서(2025년)
Mucopolysaccharidosis Treatment Global Market Report 2025
상품코드 : 1824414
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

뮤코다당증 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.9%로 성장할 전망이며, 35억 달러로 성장이 예측됩니다. 예측 기간의 성장은 유전자 편집의 진보, 규제의 변경 및 지원, 환자 접근의 대처, 새로운 치료 방식, 정밀의료 접근에 기인할 것으로 보입니다. 예측 기간 세계 동향에는 간병인 지원 프로그램, 증상 관리에 대한 주력, 교육 및 훈련 이니셔티브, 세계 액세스 확대, 바이오마커 개발의 진전 등이 포함됩니다.

향후 5년간의 성장률 7.9%라고 하는 예측은 전회 예측으로부터 0.2%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 무역 마찰은 아일랜드와 네덜란드에서 개발된 효소 보충 요법 및 기질감소제의 가격을 상승시켜 치료 중단과 유전성 질환의 치료비 상승을 초래하여 희귀질환 관리에 지장을 초래할 수 있습니다. 또한 상호 관세와 무역 긴장 증가 및 제한으로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더 광범위하게 늘어날 것으로 보입니다.

다양한 형태의 뮤코다당증 유병률 상승은 향후 뮤코다당증 치료 시장의 성장을 뒷받침할 것으로 예측됩니다. 뮤코다당증은 복합 탄수화물의 일종으로 분해에 필요한 특정 효소가 없기 때문에 신체 조직에 축적됩니다. 뮤코다당증(MPS) 치료는 다양한 치료 접근법을 통해 글리코사미노글리칸(GAG)의 축적을 억제하고, 증상을 관리하며, 합병증을 예방함으로써 질병 진행을 늦추는 데 도움이 됩니다. 예를 들어, 2024년 7월 프랑스에 본사를 둔 오픈액세스 검토 의학 잡지인 Orphanet Journal of Rare Diseases는 뮤코다당증 IVa(MPS IVa)의 이환율은 출생수 20만 1,000명에 1명으로 추정된다고 보고하고 있지만, 이 숫자는 집단에 따라 크게 다릅니다. 유사하게, 뮤코다당증 VI(MPS VI)의 출생시 유병률은 집단에 따라 다르지만, 4만 3,261명 중 1명 내지 150만 5,160명 중 1명으로 추정됩니다. 그 결과, 다양한 형태의 뮤코다당증 유병률 증가가 뮤코다당증 치료 시장을 견인할 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

The treatment of Mucopolysaccharidosis (MPS) involves addressing hereditary illnesses characterized by the body's inability to break down glycosaminoglycan (long sugar chains) due to the deficiency or malfunction of specific enzymes, often lysosomal enzymes.

Two primary types of treatments for mucopolysaccharidosis are enzyme replacement therapy and stem cell therapy. Enzyme replacement therapy is a medical intervention designed for patients with chronic diseases resulting from enzyme deficiency or dysfunction. This approach involves providing replacement enzymes to individuals affected by various forms of mucopolysaccharidosis, including types I, II, IV, VI, and others. These replacement enzymes are administered through intravenous and intracerebroventricular routes of administration. The therapy is implemented in diverse healthcare settings, including hospitals, specialty clinics, and other medical facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The mucopolysaccharidosis treatment market research report is one of a series of new reports from The Business Research Company that provides mucopolysaccharidosis treatment market statistics, including mucopolysaccharidosis treatment industry global market size, regional shares, competitors with a mucopolysaccharidosis treatment market share, detailed mucopolysaccharidosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the mucopolysaccharidosis treatment industry. This mucopolysaccharidosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mucopolysaccharidosis treatment market size has grown strongly in recent years. It will grow from $2.4 billion in 2024 to $2.58 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to enzyme replacement therapy (ERT), improved diagnostic tools, advocacy and awareness, gene therapy development, and healthcare infrastructure development.

The mucopolysaccharidosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.5 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in gene editing, regulatory changes and support, patient access initiatives, emerging therapeutic modalities, and precision medicine approaches. Major trends in the forecast period include caregiver support programs, focus on symptom management, education and training initiatives, expanded global access, and advances in biomarker development.

The forecast of 7.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder rare disease management by inflating prices of enzyme replacement therapies and substrate reduction drugs developed in Ireland and the Netherlands, resulting in treatment interruptions and higher genetic disorder care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of various forms of mucopolysaccharidosis is anticipated to boost the growth of the mucopolysaccharidosis treatment market in the future. Mucopolysaccharide is a type of complex carbohydrate that accumulates in body tissues due to the absence of the specific enzyme required for its breakdown. Mucopolysaccharidosis (MPS) therapy helps slow disease progression by reducing glycosaminoglycan (GAG) accumulation, managing symptoms, and preventing complications through various treatment approaches. For example, in July 2024, the Orphanet Journal of Rare Diseases, a peer-reviewed open-access medical journal based in France, reported that the incidence of mucopolysaccharidosis IVa (MPS IVa) is estimated at approximately 1 in 201,000 live births, although this number is believed to vary significantly across populations. Similarly, the birth prevalence of mucopolysaccharidosis VI (MPS VI) is estimated to range from 1 in 43,261 to 1 in 1,505,160, depending on the population. As a result, the increasing prevalence of different forms of mucopolysaccharidosis is expected to drive the mucopolysaccharidosis treatment market.

The rise in healthcare spending is contributing to the expansion of the mucopolysaccharidosis treatment market. Healthcare spending refers to the total financial resources dedicated to the healthcare sector within a particular region, country, or organization. The increase in healthcare spending is being directed toward mucopolysaccharidosis (MPS) treatment, aiming to improve access to specialized therapies, research, and medical infrastructure, thus enhancing the management and outcomes for individuals affected by this rare genetic disorder. For example, in July 2024, the American Medical Association, a U.S.-based professional organization of physicians and medical students, reported that health spending in the United States grew by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per capita. Therefore, the rise in healthcare spending is driving the growth of the mucopolysaccharidosis treatment market moving forward.

Product innovation is an emerging trend gaining traction in the mucopolysaccharidosis treatment market. Leading companies in this market are concentrating on developing new products to maintain their competitive edge. For example, in September 2022, Ultragenyx Pharmaceutical Inc., a U.S.-based biopharmaceutical company, launched Vestronidase alfa (Mepsevii) in Japan for the treatment of Mucopolysaccharidosis Type VII (MPS VII or Sly Syndrome). This enzyme replacement therapy is designed to address the enzyme deficiency in MPS VII, helping break down glycosaminoglycans (GAGs) and reducing their buildup in tissues and organs. Mepsevii improves patients' mobility and respiratory function, offering a transformative treatment for individuals with this rare and progressive disorder. Its approval marks a significant advancement in providing essential care for rare disease patients in Japan.

Major players in the mucopolysaccharidosis treatment market are directing their focus towards cell therapies as a promising avenue for addressing rare genetic disorders. A case in point is ISP-001, developed by Immusoft, a US-based biotechnology company. ISP-001 represents a pioneering approach utilizing cell therapy to administer gene-encoded medicine, targeting the root cause of Mucopolysaccharidosis I (MPS I). In September 2022, Immusoft achieved a significant milestone with the FDA clearance of its Investigational New Drug (IND) application for ISP-001, marking a groundbreaking advancement in engineered B cell therapy for MPS I treatment.

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics for an undisclosed sum. This acquisition is notable as it merges Kyowa Kirin's extensive experience in biopharmaceuticals with Orchard's innovative gene therapy platform, aimed at providing transformative treatments for patients with severe genetic disorders. Orchard Therapeutics, a UK-based biotech company, specializes in treatments for mucopolysaccharidosis, further enhancing the capabilities of both companies in addressing rare genetic diseases.

Major companies operating in the mucopolysaccharidosis treatment market include Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., BioMarin Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Sarepta Therapeutics Inc., Esteve SA, JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Eidos Therapeutics Inc., Neurogene Inc., Immusoft Corporation, Bioasis Technologies Inc., Paradigm Biopharmaceuticals Ltd., Rimedion Inc., Eloxx Pharmaceuticals Inc., iBio Inc., Abeona Therapeutics Inc.

North America was the largest region in the mucopolysaccharidosis treatment market in 2024. The regions covered in the mucopolysaccharidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mucopolysaccharidosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mucopolysaccharides treatment market includes revenues earned by entities by providing medication services such as enzyme replacement therapy, stem cell transplantation, gene therapy, substrate reduction therapy, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mucopolysaccharidosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mucopolysaccharidosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for mucopolysaccharidosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mucopolysaccharidosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Mucopolysaccharidosis Treatment Market Characteristics

3. Mucopolysaccharidosis Treatment Market Trends And Strategies

4. Mucopolysaccharidosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Mucopolysaccharidosis Treatment Growth Analysis And Strategic Analysis Framework

6. Mucopolysaccharidosis Treatment Market Segmentation

7. Mucopolysaccharidosis Treatment Market Regional And Country Analysis

8. Asia-Pacific Mucopolysaccharidosis Treatment Market

9. China Mucopolysaccharidosis Treatment Market

10. India Mucopolysaccharidosis Treatment Market

11. Japan Mucopolysaccharidosis Treatment Market

12. Australia Mucopolysaccharidosis Treatment Market

13. Indonesia Mucopolysaccharidosis Treatment Market

14. South Korea Mucopolysaccharidosis Treatment Market

15. Western Europe Mucopolysaccharidosis Treatment Market

16. UK Mucopolysaccharidosis Treatment Market

17. Germany Mucopolysaccharidosis Treatment Market

18. France Mucopolysaccharidosis Treatment Market

19. Italy Mucopolysaccharidosis Treatment Market

20. Spain Mucopolysaccharidosis Treatment Market

21. Eastern Europe Mucopolysaccharidosis Treatment Market

22. Russia Mucopolysaccharidosis Treatment Market

23. North America Mucopolysaccharidosis Treatment Market

24. USA Mucopolysaccharidosis Treatment Market

25. Canada Mucopolysaccharidosis Treatment Market

26. South America Mucopolysaccharidosis Treatment Market

27. Brazil Mucopolysaccharidosis Treatment Market

28. Middle East Mucopolysaccharidosis Treatment Market

29. Africa Mucopolysaccharidosis Treatment Market

30. Mucopolysaccharidosis Treatment Market Competitive Landscape And Company Profiles

31. Mucopolysaccharidosis Treatment Market Other Major And Innovative Companies

32. Global Mucopolysaccharidosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Mucopolysaccharidosis Treatment Market

34. Recent Developments In The Mucopolysaccharidosis Treatment Market

35. Mucopolysaccharidosis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기